Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
The company sees the business reaching $100mn
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
Subscribe To Our Newsletter & Stay Updated
